Feasibility of the Use of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosis

CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions

(2013) Enrique Alvarez et al.   Multiple Sclerosis Journal

Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers

(2013) Mohsen Khademi et al.   PLoS One

Tertiary lymphoid organ development coincides with determinant spreading of the myelin-specific T cell response

(2012) Stefanie Kuerten et al.   ACTA NEUROPATHOLOGICA

Immunological Markers of Optimal Response to Natalizumab in Multiple Sclerosis

(2012) Luisa M. Villar   ARCHIVES OF NEUROLOGY

Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance

(2012) Alexander Hundeshagen et al.   Journal of Neuroinflammation

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation

(2012) Markus C Kowarik et al.   Journal of Neuroinflammation

Disease Biomarkers in Multiple Sclerosis

(2012) Violaine K. Harris et al.   Molecular Diagnosis & Therapy

Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13

(2012) M Lindén et al.   Multiple Sclerosis Journal

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis

(2012) Jeppe Romme Christensen et al.   Multiple Sclerosis Journal

Increased PK11195 PET binding in the cortex of patients with MS correlates with disability

(2012) M. Politis et al.   NEUROLOGY

Serum IL-17F does not predict poor response to IM IFN -1a in relapsing-remitting MS

(2012) S. E. Bushnell et al.   NEUROLOGY

Rituximab combination therapy in relapsing multiple sclerosis

(2012) Anne H. Cross et al.   Therapeutic Advances in Neurological Disorders

The neuropathological basis of clinical progression in multiple sclerosis

(2011) Richard Reynolds et al.   ACTA NEUROPATHOLOGICA

Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis

(2011) Laura Lovato et al.   BRAIN

Altered hippocampal synaptic transmission in transgenic mice with astrocyte-targeted enhanced CCL2 expression

(2011) Thomas E. Nelson et al.   BRAIN BEHAVIOR AND IMMUNITY

Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10

(2011) Alessandro Antonelli et al.   CYTOKINE

The molecular basis of neurodegeneration in multiple sclerosis

(2011) Hans Lassmann et al.   FEBS LETTERS

Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid

(2011) Samia Ragheb et al.   Multiple Sclerosis Journal

Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes

(2011) Maria José Magraner et al.   NEURORADIOLOGY

Inflammatory Cortical Demyelination in Early Multiple Sclerosis

(2011) Claudia F. Lucchinetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis

(2010) Roberta Magliozzi et al.   ANNALS OF NEUROLOGY

Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis

(2010) Laura Piccio et al.   ARCHIVES OF NEUROLOGY

MS and the B cell controversy

(2010) Anne H. Cross et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

The blood–brain barrier, chemokines and multiple sclerosis

(2010) David W. Holman et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing−remitting multiple sclerosis patients

(2010) Alicja Kalinowska-Łyszczarz et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production

(2010) Chris J Hedegaard et al.   Multiple Sclerosis Journal

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course

(2010) Mohsen Khademi et al.   Multiple Sclerosis Journal

CCL5, CXCL10 and CXCL11 Chemokines in Patients with Active and Stable Relapsing-Remitting Multiple Sclerosis

(2010) Adam Szczuciński et al.   NEUROIMMUNOMODULATION

The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)

(2010) Johannes Brettschneider et al.   PLoS One

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study

(2009) Jason W. Bauer et al.   ARTHRITIS AND RHEUMATISM

A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis

(2009) M. Comabella et al.   BRAIN

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN

CXCL13 and CXCL12 in Central Nervous System Lymphoma Patients

(2009) L. Fischer et al.   CLINICAL CANCER RESEARCH

Serum levels of CXCL13 are elevated in active multiple sclerosis

(2009) Eugene D Festa et al.   Multiple Sclerosis Journal

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS

(2009) F. Sellebjerg et al.   NEUROLOGY

Pathological Expression of CXCL12 at the Blood-Brain Barrier Correlates with Severity of Multiple Sclerosis

(2008) Erin E. McCandless et al.   AMERICAN JOURNAL OF PATHOLOGY

Lymphoid chemokines in chronic neuroinflammation

(2008) Francesca Aloisi et al.   JOURNAL OF NEUROIMMUNOLOGY

Orchestrating the orchestrators: chemokines in control of T cell traffic

(2008) Shannon K Bromley et al.   NATURE IMMUNOLOGY

Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis

(2008) Birgit Obermeier et al.   NATURE MEDICINE

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients

(2008) Lisa G. M. van Baarsen et al.   PLoS One